Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader

Rhea-AI Filing Summary

Jazz Pharmaceuticals reported that EVP and Global Head of R&D and CMO Robert Iannone acquired 14,822 ordinary shares through a stock-based award at no cost. The grant consists of restricted stock units that convert into one ordinary share each as they vest.

The units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary and the remainder over the following three years. After this award, Iannone directly holds 95,080 ordinary shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Iannone Robert

Role EVP, Global Head of R&D & CMO

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	14,822	$0.00	--

Holdings After Transaction: Ordinary Shares — 95,080 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iannone Robert

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Head of R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/26/2026		A(1)		14,822	A	$0.0	95,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

	By: /s/Paz Dizon, as attorney in fact For: Robert Iannone	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Robert Iannone?

Jazz Pharmaceuticals reported that EVP and CMO Robert Iannone received 14,822 ordinary shares via a stock-based award. These were granted as restricted stock units at no cash cost and will convert into shares over time as the units vest according to the plan’s schedule.

How many Jazz Pharmaceuticals shares did Robert Iannone acquire in this Form 4?

Robert Iannone acquired 14,822 ordinary shares of Jazz Pharmaceuticals through a grant of restricted stock units. Each unit represents a contingent right to receive one ordinary share, subject to vesting conditions under the company’s 2011 Equity Incentive Plan over a four-year vesting period.

How do the restricted stock units granted to Robert Iannone at Jazz Pharmaceuticals vest?

The restricted stock units granted to Robert Iannone vest in four equal annual installments. Vesting is measured from a commencement date of March 5, 2026, with one-quarter vesting on the first anniversary and the remaining three-quarters vesting in equal annual installments over the following three years.

What is Robert Iannone’s total Jazz Pharmaceuticals shareholding after this award?

Following this equity award, Robert Iannone directly owns 95,080 ordinary shares of Jazz Pharmaceuticals. This total includes the impact of the newly granted 14,822 restricted stock units, which convert into ordinary shares as they vest under the company’s 2011 Equity Incentive Plan terms.

Were the Jazz Pharmaceuticals shares granted to Robert Iannone purchased on the open market?

No, the shares were not purchased on the open market. They were granted as restricted stock units under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan, with each unit representing a contingent right to receive one ordinary share upon vesting over a four-year schedule beginning March 5, 2026.